Loading...

Eagle Pharmaceuticals

DB:1E6
Snowflake Description

Excellent balance sheet with acceptable track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1E6
DB
$666M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The last earnings update was 50 days ago. More info.


Add to Portfolio Compare Print
1E6 Share Price and Events
7 Day Returns
1.6%
DB:1E6
-1.4%
DE Biotechs
2.4%
DE Market
1 Year Returns
-5%
DB:1E6
-10.6%
DE Biotechs
-6.2%
DE Market
1E6 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Eagle Pharmaceuticals (1E6) 1.6% -1.4% 11% -5% 16.8% 418.7%
DE Biotechs -1.4% 2.6% -7.7% -10.6% 54.2% 8%
DE Market 2.4% 3% 7.4% -6.2% 9.6% 14.1%
1 Year Return vs Industry and Market
  • 1E6 outperformed the Biotechs industry which returned -10.6% over the past year.
  • 1E6 outperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
1E6
Industry
5yr Volatility vs Market

1E6 Value

 Is Eagle Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Eagle Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Eagle Pharmaceuticals.

DB:1E6 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.3%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:1E6
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 21%) (6.67%))
1.351
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.35
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.351 * 5.96%)
8.28%

Discounted Cash Flow Calculation for DB:1E6 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Eagle Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:1E6 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.28%)
2019 75.00 Analyst x1 69.26
2020 72.50 Analyst x1 61.84
2021 81.50 Analyst x1 64.20
2022 84.20 Analyst x1 61.25
2023 70.60 Analyst x1 47.43
2024 70.46 Est @ -0.2% 43.72
2025 70.40 Est @ -0.07% 40.34
2026 70.42 Est @ 0.02% 37.26
2027 70.47 Est @ 0.08% 34.44
2028 70.56 Est @ 0.12% 31.85
Present value of next 10 years cash flows $491.59
DB:1E6 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $70.56 × (1 + 0.23%) ÷ (8.28% – 0.23%)
$878.30
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $878.30 ÷ (1 + 8.28%)10
$396.43
DB:1E6 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $491.59 + $396.43
$888.02
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $888.02 / 13.92
$63.77
DB:1E6 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:1E6 represents 0.8812x of NasdaqGM:EGRX
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.8812x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 63.77 x 0.8812
€56.20
Value per share (EUR) From above. €56.20
Current discount Discount to share price of €42.13
= -1 x (€42.13 - €56.20) / €56.20
25%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Eagle Pharmaceuticals is available for.
Intrinsic value
25%
Share price is €42.13 vs Future cash flow value of €56.2
Current Discount Checks
For Eagle Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Eagle Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Eagle Pharmaceuticals's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Eagle Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Eagle Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:1E6 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $2.16
NasdaqGM:EGRX Share Price ** NasdaqGM (2019-04-18) in USD $47.81
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.41x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.67x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Eagle Pharmaceuticals.

DB:1E6 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:EGRX Share Price ÷ EPS (both in USD)

= 47.81 ÷ 2.16

22.13x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Eagle Pharmaceuticals is good value based on earnings compared to the Europe Biotechs industry average.
  • Eagle Pharmaceuticals is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Eagle Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:1E6 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 22.13x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
13%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

DB:1E6 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 22.13x ÷ 13%

1.7x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Eagle Pharmaceuticals is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Eagle Pharmaceuticals's assets?
Raw Data
DB:1E6 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $11.55
NasdaqGM:EGRX Share Price * NasdaqGM (2019-04-18) in USD $47.81
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.85x
DB:1E6 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:EGRX Share Price ÷ Book Value per Share (both in USD)

= 47.81 ÷ 11.55

4.14x

* Primary Listing of Eagle Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Eagle Pharmaceuticals is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Eagle Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Eagle Pharmaceuticals has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

1E6 Future Performance

 How is Eagle Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Eagle Pharmaceuticals expected to grow at an attractive rate?
  • Eagle Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Eagle Pharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • Eagle Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:1E6 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:1E6 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 13%
DB:1E6 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 5%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:1E6 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:1E6 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 255 90 2
2022-12-31 275 90 2
2021-12-31 253 86 4
2020-12-31 241 84 41 5
2019-12-31 217 70 27 5
DB:1E6 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 213 52 32
2018-09-30 204 40 28
2018-06-30 216 44 30
2018-03-31 207 76 32
2017-12-31 237 59 52
2017-09-30 271 73 100
2017-06-30 246 78 97
2017-03-31 237 38 105
2016-12-31 189 53 81
2016-09-30 127 -3 25
2016-06-30 94 -23 3
2016-03-31 60 -32 -18

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Eagle Pharmaceuticals's earnings are expected to grow by 13% yearly, however this is not considered high growth (20% yearly).
  • Eagle Pharmaceuticals's revenue is expected to grow by 5% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:1E6 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Eagle Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1E6 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 2.64 2.64 2.64 1.00
2019-12-31 1.88 1.88 1.88 1.00
DB:1E6 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 2.16
2018-09-30 1.91
2018-06-30 2.00
2018-03-31 2.11
2017-12-31 3.44
2017-09-30 6.59
2017-06-30 6.30
2017-03-31 6.82
2016-12-31 5.24
2016-09-30 1.63
2016-06-30 0.21
2016-03-31 -1.16

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Eagle Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Eagle Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Eagle Pharmaceuticals has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

1E6 Past Performance

  How has Eagle Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Eagle Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Eagle Pharmaceuticals has delivered over 20% year on year earnings growth in the past 5 years.
  • Eagle Pharmaceuticals's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Eagle Pharmaceuticals's 1-year earnings growth is negative, it can't be compared to the Europe Biotechs industry average.
Earnings and Revenue History
Eagle Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Eagle Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1E6 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 213.31 31.90 60.51 44.42
2018-09-30 204.04 28.40 58.35 48.00
2018-06-30 215.73 29.79 61.14 50.98
2018-03-31 206.54 31.64 68.03 42.40
2017-12-31 236.71 51.94 71.42 32.61
2017-09-30 271.06 100.16 77.13 37.84
2017-06-30 245.88 96.68 71.04 33.18
2017-03-31 236.68 105.27 59.94 30.29
2016-12-31 189.48 81.45 53.33 28.29
2016-09-30 126.52 25.37 39.91 22.39
2016-06-30 94.42 3.25 34.79 25.01
2016-03-31 59.51 -18.02 28.15 27.09
2015-12-31 66.23 2.57 20.17 27.86
2015-09-30 54.04 -4.01 18.86 23.43
2015-06-30 51.12 -2.95 17.25 22.41
2015-03-31 50.51 2.15 14.20 20.70
2014-12-31 19.60 -20.62 12.28 18.59
2014-09-30 19.10 -19.64 9.33 16.82
2014-06-30 17.43 -11.19 4.30 14.35
2014-03-31 20.21 -8.57 2.88 11.43
2013-12-31 17.69 -10.97 4.37 10.17
2013-09-30 13.68 -9.89 4.96 9.80
2013-06-30 10.34 -14.43 7.95 8.94
2012-09-30 2.54 -23.32 6.40 12.81

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Eagle Pharmaceuticals has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Eagle Pharmaceuticals used its assets more efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • Eagle Pharmaceuticals has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Eagle Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Eagle Pharmaceuticals has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

1E6 Health

 How is Eagle Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Eagle Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Eagle Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Eagle Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Eagle Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Eagle Pharmaceuticals Company Filings, last reported 3 months ago.

DB:1E6 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 160.76 44.41 78.79
2018-09-30 194.07 44.31 91.23
2018-06-30 185.73 46.72 100.25
2018-03-31 178.18 47.87 95.67
2017-12-31 179.14 47.78 114.66
2017-09-30 171.08 48.94 97.55
2017-06-30 165.36 0.00 55.39
2017-03-31 166.83 0.00 27.71
2016-12-31 151.23 0.00 52.82
2016-09-30 105.52 0.00 59.31
2016-06-30 107.83 0.00 75.56
2016-03-31 92.32 0.00 78.29
2015-12-31 90.34 0.00 79.08
2015-09-30 87.63 0.00 95.98
2015-06-30 96.45 0.00 103.69
2015-03-31 102.88 0.00 115.92
2014-12-31 27.91 0.00 34.87
2014-09-30 33.10 0.00 42.72
2014-06-30 41.91 0.00 49.79
2014-03-31 44.69 0.00 54.88
2013-12-31 0.77 0.00 9.97
2013-09-30 3.76 0.00 10.46
2013-06-30 2.26 0.00 10.80
2012-09-30 -11.44 8.57 6.57
  • Eagle Pharmaceuticals's level of debt (27.6%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 27.6% today).
  • Debt is well covered by operating cash flow (118%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 18x coverage).
X
Financial health checks
We assess Eagle Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Eagle Pharmaceuticals has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

1E6 Dividends

 What is Eagle Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Eagle Pharmaceuticals dividends.
If you bought €2,000 of Eagle Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Eagle Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Eagle Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:1E6 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:1E6 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Eagle Pharmaceuticals has not reported any payouts.
  • Unable to verify if Eagle Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Eagle Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Eagle Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Eagle Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Eagle Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Eagle Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

1E6 Management

 What is the CEO of Eagle Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Scott Tarriff
COMPENSATION $8,041,928
AGE 58
TENURE AS CEO 12.3 years
CEO Bio

Mr. Scott L. Tarriff founded Eagle Pharmaceuticals Inc. in January 2007 and has been its Chief Executive Officer since January 2007. Mr. Tarriff served as the Chief Executive Officer and President at Par Pharmaceutical Companies Inc. from September 16, 2003 to September 2006. He served as the President of Eagle Pharmaceuticals Inc., from January 2007 to January 02, 2017. He also served as an Executive Vice President of Par Pharmaceutical Companies Inc. since January 1998. He served as Executive Vice President of Business, Chief Executive Officer and President of Par Pharmaceutical Inc., a subsidiary of Par Pharmaceutical Companies, Inc. since September 2001. He joined Par Pharmaceutical Companies in 1998. From 1995 to 1997, Mr. Tarriff served as Senior Director of Marketing Business Development and Strategic Planning of the Apothecon division at Bristol-Myers Squibb. He has more than 25 years of pharmaceutical experience. He served as the Chairman and Director of Kali Laboratories, Inc., a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. Mr. Tarriff serves as a Director of Hillcrest Health Service System, Inc. He has been a Director of ZIOPHARM Oncology, Inc. since September 28, 2015 and has been its Lead Director since August 2, 2018. He has been an Director of Eagle Pharmaceuticals Inc., since January 2007. He has been an Independent Director at Synthetic Biologics, Inc. (Formerly, Adeona Pharmaceuticals, Inc.) since February 3, 2012. Mr. Tarriff served as Director of Par Pharmaceutical Companies Inc. from 2002 to September 2006. He served as a Director of Clinical Data, Inc. from September 2009 to April 13, 2011. He has been recognized as a visionary leader in the pharmaceutical industry where his marketing and business development expertise has been utilized to set new standards and to provide greater value for customers and stakeholders. He serves as Member of Board of Governors and Member of Advisory Board of Hackensack University Medical Center. Mr. Tarriff holds and a B.S. in Marketing from Pennsylvania State University and an MBA from Rider College.

CEO Compensation
  • Scott's compensation has been consistent with company performance over the past year.
  • Scott's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Eagle Pharmaceuticals management team in years:

2.3
Average Tenure
57
Average Age
  • The tenure for the Eagle Pharmaceuticals management team is about average.
Management Team

Scott Tarriff

TITLE
CEO & Director
COMPENSATION
$8M
AGE
58
TENURE
12.3 yrs

David Pernock

TITLE
President & Chief Operating Officer
COMPENSATION
$4M
AGE
65
TENURE
2.3 yrs

Pete Meyers

TITLE
Chief Financial Officer
COMPENSATION
$2M
AGE
48
TENURE
1.9 yrs

Adrian Hepner

TITLE
Executive VP & Chief Medical Officer
COMPENSATION
$3M
AGE
57
TENURE
4.3 yrs

Dan O'Connor

TITLE
Executive Vice President of Biologics & Corporate Development
AGE
38
TENURE
1.9 yrs

Reiner Nowak

TITLE
Executive
COMPENSATION
$12K
Board of Directors Tenure

Average tenure and age of the Eagle Pharmaceuticals board of directors in years:

2.8
Average Tenure
57
Average Age
  • The average tenure for the Eagle Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

Mike Graves

TITLE
Chairman
COMPENSATION
$458K
AGE
55
TENURE
2.8 yrs

Scott Tarriff

TITLE
CEO & Director
COMPENSATION
$8M
AGE
58
TENURE
12.3 yrs

Steven Ratoff

TITLE
Director
COMPENSATION
$400K
AGE
75
TENURE
12.1 yrs

Sander Flaum

TITLE
Director
COMPENSATION
$398K
AGE
81
TENURE
12.1 yrs

Doug Braunstein

TITLE
Director
COMPENSATION
$385K
AGE
57
TENURE
2.8 yrs

Robert Glenning

TITLE
Director
COMPENSATION
$394K
AGE
57
TENURE
2.8 yrs

Richard Edlin

TITLE
Director
COMPENSATION
$363K
AGE
56
TENURE
2.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Eagle Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Eagle Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

1E6 News

Simply Wall St News

1E6 Company Info

Description

Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin’s lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Details
Name: Eagle Pharmaceuticals, Inc.
1E6
Exchange: DB
Founded: 2007
$591,958,750
13,924,296
Website: http://www.eagleus.com
Address: Eagle Pharmaceuticals, Inc.
50 Tice Boulevard,
Suite 315,
Woodcliff Lake,
New Jersey, 07677,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM EGRX Common Stock Nasdaq Global Market US USD 12. Feb 2014
DB 1E6 Common Stock Deutsche Boerse AG DE EUR 12. Feb 2014
Number of employees
Current staff
Staff numbers
96
Eagle Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 21:51
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/17
Last earnings filing: 2019/02/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.